Merck's $688M Vytorin Settlement Wins Judge's Nod

Law360, New York (October 1, 2013, 9:39 PM EDT) -- A New Jersey federal judge on Tuesday approved a $688 million settlement to settle claims that Merck & Co. Inc. and its subsidiary Schering-Plough Corp. concealed test results on the efficacy of their anti-cholesterol drug Vytorin, while also awarding $140 million in attorneys’ fees.

U.S. District Court Judge Dennis M. Cavanaugh signed a trio of orders Tuesday, one approving the $688 million settlement Merck and Schering-Plough offered in February just prior to the class action’s trial date, and two more to grant attorneys’ fees and court...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.